- Home
- GPCR vs XERS Comparison
GPCR vs XERS Comparison
Compare GPCR & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPCR
- XERS
- Stock Information
- Founded
- GPCR 2016
- XERS 2005
- Country
- GPCR United States
- XERS United States
- Employees
- GPCR N/A
- XERS N/A
- Industry
- GPCR
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- GPCR
- XERS Health Care
- Exchange
- GPCR Nasdaq
- XERS Nasdaq
- Market Cap
- GPCR 1.2B
- XERS 1.3B
- IPO Year
- GPCR 2023
- XERS 2018
- Fundamental
- Price
- GPCR $30.52
- XERS $7.97
- Analyst Decision
- GPCR Strong Buy
- XERS Strong Buy
- Analyst Count
- GPCR 8
- XERS 7
- Target Price
- GPCR $69.57
- XERS $8.00
- AVG Volume (30 Days)
- GPCR 1.0M
- XERS 2.2M
- Earning Date
- GPCR 11-12-2025
- XERS 11-07-2025
- Dividend Yield
- GPCR N/A
- XERS N/A
- EPS Growth
- GPCR N/A
- XERS N/A
- EPS
- GPCR N/A
- XERS N/A
- Revenue
- GPCR N/A
- XERS $246,025,000.00
- Revenue This Year
- GPCR N/A
- XERS $43.89
- Revenue Next Year
- GPCR N/A
- XERS $20.40
- P/E Ratio
- GPCR N/A
- XERS N/A
- Revenue Growth
- GPCR N/A
- XERS 35.62
- 52 Week Low
- GPCR $13.22
- XERS $2.82
- 52 Week High
- GPCR $42.57
- XERS $8.51
- Technical
- Relative Strength Index (RSI)
- GPCR 72.59
- XERS 51.52
- Support Level
- GPCR $25.67
- XERS $7.90
- Resistance Level
- GPCR $30.93
- XERS $8.46
- Average True Range (ATR)
- GPCR 1.81
- XERS 0.33
- MACD
- GPCR 0.33
- XERS -0.05
- Stochastic Oscillator
- GPCR 94.40
- XERS 31.65
About GPCR Structure Therapeutics Inc.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).